Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

15 Sep 2023

Dual Excipient Integration in Dry Powder Inhaler Products


The pharmaceutical industry is witnessing a significant shift in the formulation of dry powder inhaler (DPI) products, with a move from single excipients to dual excipient platforms. This evolution is not merely a trend, but a response to the need for improved performance of DPIs, which are critical in the treatment of respiratory diseases.


The article “Dual Excipient Integration in Dry Powder Inhaler Products” provides an in-depth exploration of this transition, highlighting the crucial role of excipients in enhancing the performance of DPIs. The challenges faced in DPI formulation are not to be underestimated, but the right choice of excipients can pave the way to overcoming these obstacles.


The publication also explores the intricacies of single and dual excipient platforms, providing valuable insights that are indispensable for researchers, pharmaceutical companies, and healthcare professionals interested in respiratory drug delivery. 

The future of DPI product development is also discussed, offering a glimpse into what lies ahead in this exciting field.


Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »